Skip to content
OpenCapital
Get started

Denali Therapeutics Inc. DNLI R&D

R&D at other companies

Eli Lilly logo
Eli LillyLLY
$3.51B+28.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.54B+16.3%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$150.15M+263%
uniQure logo
uniQureQURE
$29.18M-19.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$126.64M+13.6%
Biogen logo
BiogenBIIB
$539M+24.2%

Segments

By segment

See full
Therapeutics Segment$103.85M-10.7%

Other financials

Income statement

See full
Revenue-—
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0×0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s R&D?
Denali Therapeutics Inc. (DNLI) reported R&D of $103.85M in Q1 2026.
How has Denali Therapeutics Inc.'s R&D changed year-over-year?
Denali Therapeutics Inc.'s R&D decreased by 10.7% year-over-year, from $116.23M to $103.85M.
What is the long-term trend for Denali Therapeutics Inc.'s R&D?
Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s R&D has grown at a 12.1% compound annual growth rate (CAGR), from $265.35M to $418.78M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.